Pharmaceuticals company FDC announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Operating Revenue increased by 6.5%, from Rs 462 crore to Rs 492 crore. EBITDA declined by 4.2%, from Rs 56 crore to Rs 54 crore. EBITDA Margin dropped from 12.2% to 11.0%. PBT (Profit Before Tax) fell 18.3%, from Rs 65 crore to Rs 53 crore. PAT (Profit After Tax) declined 16.5%, from Rs 46 crore to Rs 39 crore. EPS decreased 16.5%, from Rs 2.84 to Rs 2.38. FY25 Financial Highlights: Operating Revenue rose by 8.5%, from Rs 1,943 crore to Rs 2,108 crore. EBITDA declined by 4.1%, from Rs 339 crore to Rs 325 crore. EBITDA Margin reduced from 17.4% to 15.4%. PBT declined by 9.8%, from Rs 396 crore to Rs 357 crore. PAT dropped by 12.5%, from Rs 305 crore to Rs 267 crore. EPS fell by 11.8%, from Rs 18.58 to Rs 16.39. Management Commentary We’re pleased to share that your Company crossed the 22,000 crore revenue mark in FY25, growing 8.5% to reach 32,108 crore. This milestone reflects the continued strength of our India Formulations business, which contributed 84% of sales and growing with 14.4% YoY, and strong momentum in our API segment, which grew 21.1% YoY. Export Formulation business however reported decline of 25.6% YoY primarily due to lower sales in US market and few of the ROW markets. Lower sales in US market were majorly due to regulatory issues. The regulatory issues of US market have now been addressed, and management believe the business should be back in its normal flow in the coming financial year. Profitability during the year was impacted primarily due to drop in the Export formulation business, reduction in price of Electral due to NLEM price revision announcement during QI1FY25, and higher employee costs in view of moderate expansion in field force in certain clusters of India market. Result PDF
Pharmaceuticals company FDC announced Q3FY25 results Operating Revenue for Q3FY25 stood at Rs 464 crore, registering a 1.3% YoY growth from Rs 458 crore in Q3FY24. EBITDA for Q3FY25 stood at Rs 47 crore, down 44.3% YoY from Rs 84 crore. EBITDA Margin contracted to 10.1% from 18.3% YoY. Profit Before Tax (PBT) declined 47.5% YoY to Rs 51 crore, compared to Rs 98 crore. Profit After Tax (PAT) dropped 53.2% YoY to Rs 37 crore from Rs 79 crore. Earnings Per Share (EPS) decreased 53.2% YoY to Rs 2.28, compared to Rs 4.86. Management Commentary: The company delivered revenue growth of 9.1% in 9MFY25, driven by robust performance across all business segments, except for US Formulations. The export formulations business witnessed a 20.7% YoY decline in 9MFY25, primarily due to lower sales in the US market. On the other hand, the API business demonstrated strong momentum, recording a 25.6% YoY growth in Q3FY25 and 25.1% YoY growth in 9MFY25. EBITDA for Q3FY25 and 9MFY25 was impacted by lower sales in export formulation business, price reduction in the Electral range of products, driven by NLEM price revisions changes in the product mix, and higher employee costs. Result PDF